WHO WE ARE

A breakthrough alliance

T2EVOLVE works to accelerate development and increase access to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR).

T2EVOLVE: The consortium explained

T2EVOLVE consists of 27 European partners from 9 different countries in 8 work packages. Hear from different parts of the consortium here.

Latest outcomes from T2EVOLVE

The exciting future ahead for cellular therapy – from EBMT24

The 50th Annual Meeting of the EBMT ended last week showcasing a series of insightful presentations on cellular therapy, including in presentations by T2EVOLVE during the CART initiatives session. T2EVOLVE Scientific Project Manager Maik Luu was also featured on EBMT...

How to find reliable CAR T-information online – a T2EVOLVE video

T2EVOLVE has released an explainer video on how to find relevant and reliable information about CAR T-cell therapy online. The video is available in 6 different languages on the T2EVOLVE Patient Hub. Why is the video important?  Although the Internet can be a great...

See T2EVOLVE’s recommendations for cutting red tape for CAR T-therapy

New cell and gene therapies currently face many regulatory hurdles on the way to getting to market. This article published by the Innovative Health Initiative (IHI) outlines T2EVOLVE's recommendations to adjust regulatory processes and enable more developments of new...

Lymphodepletion: New article emphasises its essential but undervalued part of the CAR T-cell therapy cycle

T2EVOLVE's latest article tackles one of the most important topics in CAR T-cell therapy: lymphodepletion. While looking into 1271 studies with regard to lymphodepletion stratgies, the authors found that the variability and insufficient amount of detailed information...

Explore T2EVOLVE’s hubs for patients and HCPs

One of the T2EVOLVE consortium's key objectives is to ensure patients have access to the best available care, and being able to provide relevant and reliable information for patients and healthcare professionals is vital in making sure this happens. Because of this,...

Publications

Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy

Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy

Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations

Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: results from the phase Ib PORTIA study

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: results from the phase Ib PORTIA study

mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans

CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans

CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses

CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses

Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis

Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis

CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells and Correlates with Clinical Outcome

CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells and Correlates with Clinical Outcome

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia

Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell

Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models

Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome

CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome

Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients

Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients

CAR T-cell therapy

Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.

For additional information on CAR T-cell technology please contact UKW.

Leadership

Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany

Prof Michael Hudecek, MD

T2EVOLVE Project Coordinator

Translational Strategy Leader, Cell Therapies, Takeda Pharmaceuticals, and EFPIA project leader for T2EVOLVE IMI Consortium,
Cambridge, Massachusetts, USA

Dr Rashmi Choudhary, Ph.D.

T2EVOLVE Project Leader

Funding

This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programe and EFPIA. More information can be found at: https://www.imi.europa.eu/

Share This